RDY News 42.15 Dr. Reddy's Laboratories Ltd (RDY)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Dr. Reddy's Laboratories Ltd (RDY) 42.15 $RDY

Dr. Reddy's Launches Generic Lunesta - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 11:44AM CDT
Dr. Reddy's Labs announced the launch of its therapeutic equivalent generic version of Sunovion Pharmaceuticals Inc.'s Lunesta tablets

Dr Reddy's reports availability of FDA approved Eszopiclone tablets C-IV
M2 - Thu Apr 17, 5:08AM CDT
Pharmaceutical company Dr Reddy's Laboratories (NYSE:RDY) stated on Wednesday that it has introduced its US Food & Drug Administration (USFDA) approved Eszopiclone Tablets (C-IV) 1 mg, 2 mg and 3 mg in the US market.

Mylan Inks Two Separate Agreements - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 10:10AM CDT
Mylan entered into two separate agreements with Prosonix and Actavis.

Wednesday’s Top Health Care Stories: Zogenix, Endo, and Teva
Leo Sun, The Motley Fool - Motley Fool - Wed Apr 16, 8:21AM CDT
Let's take a quick look at three stocks -- Zogenix , Endo International , and Teva Pharmaceutical -- which could all loom large in health care headlines this morning. Zogenix surges after a U.S. court reverses the Massachusetts ban on...

Dr. Reddy's Announces the Launch of Eszopiclone Tablets C-IV
Business Wire - Wed Apr 16, 1:29AM CDT
Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched Eszopiclone Tablets (C-IV) 1 mg, 2 mg and 3 mg, a therapeutic equivalent generic version of LUNESTA(R) (eszopiclone) tablets C-IV in the US market on April 15, 2014, following the approval by the United States Food & Drug Administration (USFDA).

Mylan to Settle with Endo on Frova - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 10:40AM CDT
A federal district court granted Mylan's request to forge a settlement with Endo regarding Frova.

Teva to Launch Generic Lovaza - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 3:45PM CDT
Teva Pharmaceutical announced that the FDA has approved its generic version of Lovaza.

Mallinckrodt plc (MNK) in Focus: Stock Moves 5.3% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 7:37AM CDT
Mallinckrodt plc as the company saw its shares rise more than 5% on the day.

Product Launches, Acquisitions, Closed Offerings, Divestitures, and Financial Results - Analyst Notes on Dr. Reddy's, ICON, Endocyte, BioScrip, and DepoMed
PR Newswire - Mon Apr 07, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Dr. Reddy's Laboratories Ltd. (NYSE: RDY), ICON plc (NASDAQ: ICLR), Endocyte, Inc. (NASDAQ: ECYT), BioScrip Inc. (NASDAQ: BIOS), and DepoMed Inc. (NASDAQ: DEPO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Mylan to Buy Swedish Company? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 10:30AM CDT
According to a report in the Financial Times, Mylan is looking to acquire Meda AB.

Dr. Reddy's Launches Generic Caduet - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 1:07PM CDT
Dr. Reddy's announced the launch of its therapeutic equivalent generic version of Pfizer's Caduet

Weakness Seen in Relypsa (RLYP): Stock Plunges 19.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 7:42AM CDT
Relypsa (RLYP) fell over 19% in the last trading session amid high volumes, breaking its recent volatile trend as it is currently trading below the volatile price range of last one month.

Dr. Reddy's Announces the Launch of Amlodipine Besylate and Atorvastatin Calcium Tablets
Business Wire - Thu Mar 27, 3:11AM CDT
Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched Amlodipine Besylate and Atorvastatin Calcium Tablets 2.5/10mg, 2.5/20mg, 2.5/40mg, 5/10mg, 5/20mg, 5/40mg, 5/80mg, 10/10mg, 10/20mg, 10/40mg and 10/80 mg a therapeutic equivalent generic version of CADUET(R) (amlodipine Besylate and atorvastatin calcium) tablets, in the US market on March 26, 2014, following the approval by the United States Food & Drug Administration (USFDA).

Actavis-Valeant Antibiotic Approved - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 4:40PM CDT
Actavis and Valeant Pharma announced that the FDA has cleared metronidazole 1.3% vaginal gel.

Relypsa (RLYP) in Focus: Stock Adds 12.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 8:46AM CDT
Relypsa was a big mover last session, with shares rising over 12% on the day.

Galena Biopharma Earnings Report: "P.S. -- We're Under Investigation"
Keith Speights, The Motley Fool - Motley Fool - Thu Mar 20, 5:30PM CDT
It pays to read the fine print. Galena Biopharma reported its fourth-quarter results after the market closed on Monday. There were plenty of financial numbers to digest, of course, and a few interesting updates on the company's products and...

FDA Approves Mallinckrodt's Xartemis XR - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 5:00PM CDT
Mallinckrodt's Xartemis XR was approved by the U.S. Food and Drug Administration (FDA) for the management of acute pain in patients requiring opioid treatment and for whom alternative therapies are inadequate, ineffective or are not tolerated.

Zacks Rank #1 Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday

Shares of RDY Up 34.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Mar 05, 11:07AM CST
SmarTrend identified an Uptrend for Dr Reddys Laboratories (NYSE:RDY) on September 5th, 2013 at $34.42. In approximately 6 months, Dr Reddys Laboratories has returned 34.25% as of today's recent price of $46.21.

Dr. Reddy's reports market availibility of US FDA approved Moxifloxacin Hydrochloride Tablets 400 mg
M2 - Wed Mar 05, 6:21AM CST
Pharmaceutical company Dr. Reddy's Laboratories (NYSE:RDY) disclosed on Wednesday that it has unveiled its Moxifloxacin Hydrochloride Tablets 400 mg in bottle counts of 30 in the US market.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Babe Ruth Lots Lead Morphy's $2 Million Collectibles Auction

Updated Category News Views 0

Ruth still pulls money like few names ever will, and Morphy's November 10-12 auction made that plain without any circus tricks. Three lots tied to the Yankees legend produced $136,500 within a Toys, Sports & General Collectibles sale that topped $2 million. That is not some vague nostalgia story. Buyers put real dollars behind a 1932 U.S. Caramel card, a 1933 Goudey card,...

Continue Reading
CMS Audit Proposal Reopens Medicare Advantage Risk

Updated Category News Views 104

A regulator just tossed a rusted anchor into managed care's earnings model. CMS's proposed Comprehensive Regulations to Uncover Suspicious Healthcare rule, dubbed CRUSH and numbered CMS-6098-P, puts Medicare Advantage risk-adjustment audits back at center stage. The headline nobody can casually wave away: audit findings from sampled enrollees could be extrapolated across...

Continue Reading
PG&E's $456 Million Interim Hike Faces a New Test Soon

Updated Category News Views 138

A utility can call a charge interim, but households still see the bill arrive in full. That is why the California Public Utilities Commission's unanimous approval of $456 million in interim rate recovery for Pacific Gas & Electric has landed with such rotten timing. The money is set to begin flowing from customers on January 1, 2027, while major questions about PG&E's...

Continue Reading
Cybersecurity's AI Tailwind Meets a Brutal Market Test

Updated Category News Views 89

Security software caught a bid while the rest of the tape was getting kicked down the stairs. That contrast is the whole story: investors saw Palo Alto Networks deliver a strong fiscal first quarter and raise its fiscal 2027 outlook, then decided cyber defense may be one of the few technology budgets companies cannot casually postpone. With AI helping attackers locate and...

Continue Reading
Gene Editing’s Steady Revenue Engine Is Taking Shape

Updated Category News Views 112

Gene editing is finally starting to look less like a science-fair moonshot and more like a working supply chain. That distinction matters. The latest market estimate puts the global gene editing market at $5.23 billion in 2026 and projects $8.49 billion by 2031, a 10.1% compound annual growth rate. Respectable growth, certainly, but the real investment story is not a...

Continue Reading
IAS Marks 42 Years Amid Germany Religious Freedom Win

Updated Category News Views 96

Bagpipes, country roads and a gathering from six continents made this far more than a routine anniversary reception. The International Association of Scientologists marked its 42nd anniversary at Saint Hill in East Grinstead, England, with thousands of Scientologists and guests arriving as autumn settled over West Sussex. That sort of turnout is a visible statement of...

Continue Reading
Dario's Personify Panel Puts Distribution Model in Focus

Updated Category News Views 121

A Partner Megaphone Is Not a Revenue Line Monday's virtual panel gives DarioHealth a useful stage, but investors should not confuse a conference microphone with a signed sales order. Erez Raphael is set to lead a November 23 discussion with Personify Health President Ed Liebowitz at the U.S. Bancorp | BTIG Tech-Enabled Healthcare Forum, running from noon to 12:50 p.m....

Continue Reading
Mobile Core's Cost Crunch Favors Telecom's Big Three

Updated Category News Views 45

Server bills have finally crashed the party in mobile core, and nobody should pretend that is a minor inconvenience. Dell'Oro Group's 3Q 2026 read is blunt: Mobile Core Network revenue growth was lackluster because 5G spending came in below expectations, while higher server costs pushed operators to reshuffle priorities, postpone projects, and keep 4G core gear alive...

Continue Reading
PTC Pushes Deeper Into Federal Product Development

Updated Category News Views 82

Federal engineering software is a miserable place to show up late, and PTC is plainly trying not to. Its November 19, 2026 expansion brings Windchill+ onto Microsoft Azure Government through PTC Cloud Services and introduces Onshape Government Federal for teams handling Controlled Unclassified Information. This is not a glamorous product refresh. It is a bid to remove the...

Continue Reading
A. O. Smith's Sustainability Scorecard Has Real Teeth

Updated Category News Views 130

Numbers finally showed up wearing work boots in A. O. Smith’s latest sustainability report. The company says it beat every one of its three environmental targets, and the gaps were not the sort of rounding-error victories corporate communications teams love to polish until they shine. For investors following NYSE:AOS, that deserves a look—not a standing ovation, but a...

Continue Reading

Top 5 Most Recently Viewed Articles

Projected Growth in Edge Data Center Market Through 2029

Updated Category News Views 227

Edge Data Center Market Outlook and Growth Drivers The edge data center market is set to witness impressive growth, with projections estimating an increase of USD 45.1 billion from 2025 to 2029. This surge is driven primarily by the rising demand for video streaming services and the incorporation of artificial intelligence (AI) in data center operations. Market Trends...

Continue Reading
Uncertainties Loom as U.S. Economy Reacts to Job Data Shift

Updated Category News Views 73

Economic Uncertainties Fueling Market Volatility Recent fluctuations in the U.S. economy have raised fresh concerns among investors, particularly as key employment data shows an unexpected slowdown. This situation has intensified worries about the Federal Reserve's monetary policies and the approaching U.S. presidential election season, creating a tough environment for...

Continue Reading
SME Insurance Market Expected to Surge to $45.60 Billion

Updated Category News Views 96

Growth of the SME Insurance Market Recent data shows that the global SME insurance market, currently valued at around USD 28 billion, is projected to surge to USD 45.60 billion in the coming years. This significant growth is primarily driven by the rising number of small and medium enterprises (SMEs) that need comprehensive insurance solutions to protect themselves from...

Continue Reading
Unlocking High-Yield Potential with CoinEx Dual Investment

Updated Category News Views 199

Introducing CoinEx Dual Investment CoinEx, a leading cryptocurrency exchange, has unveiled its latest offering: CoinEx Dual Investment. This innovative investment product is tailored for users seeking to maximize their returns through a unique dual-currency settlement structure. With the cryptocurrency market showing constant fluctuations, this new option empowers users...

Continue Reading
Shelby County Federal Credit Union Enhances Leadership for Growth

Updated Category News Views 160

Welcoming a New Era at Shelby County Federal Credit Union Shelby County Federal Credit Union is beginning an exciting chapter as it welcomes its newly appointed Chief Executive Officer, Raffael Crockett. With more than thirty years in the credit union sector, Crockett is renowned for his transformational leadership capabilities. His vision is set on enhancing the...

Continue Reading